

NOVEL FORMULATIONS FOR OPIOID-BASED TREATMENTS OF PAIN
COMPRISING SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE
DERIVATIVES.

5

Field of the Invention

This invention concerns novel formulations for opioid-based treatments of pain and/or nociception comprising opioid analgesics and 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK₁ antagonistic activity, the use of said formulation for the manufacture of a medicament for the prevention and/or treatment of emesis, in particular nausea and vomiting, pain and/or nociception, in particular in opioid-based acute and chronic pain treatments, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments and the use of an NK₁-receptor antagonist for the manufacture of a medicament for the prevention and/or treatment of emesis, in particular nausea and vomiting, respiratory depression and tolerance in opioid-based treatments of pain.

Background of The Invention

Opioid analgesics are the cornerstone of pain treatment, especially in the segment of moderate to severe acute and chronic pain. However, side-effects such as nausea/vomiting, constipation, respiratory depression and tolerance limit their use. The lowering of the high incidence of nausea and vomiting with many clinically used opioids is particularly considered as a major unmet medical need.

25

Neurokinins belong to a family of short peptides that are widely distributed in the mammalian central and peripheral nervous system (Bertrand and Geppetti, *Trends Pharmacol. Sci.* 17:255-259 (1996) ; Lundberg, *Can. J. Physiol. Pharmacol.* 73:908-914 (1995) ; Maggi, *Gen. Pharmacol* 26:911-944 (1995) ; Regoli *et al.*, *Pharmacol. Rev.* 46 (1994)). They share the common C-terminal sequence Phe-Xaa-Gly-Leu-Met-NH₂. Neurokinins released from peripheral sensory nerve endings are believed to be involved in neurogenic inflammation. In the spinal cord/central nervous system, neurokinins may play a role in pain transmission/perception and in some autonomic reflexes and behaviors. The three major neurokinins are Substance P (SP), Neurokinin A (NK_A) and Neurokinin B (NK_B) with preferential affinity for three distinct receptor subtypes, termed NK₁, NK₂, and NK₃, respectively. However, functional studies on cloned receptors suggest strong functional cross-interaction between the 3 neurokinins

-2-

and their corresponding receptors (Maggi and Schwartz, *Trends Pharmacol. Sci.* **18**: 351-355 (1997)). Species differences in structure of NK₁ receptors are responsible for species-related potency differences of NK₁ antagonists (Maggi, *Gen. Pharmacol.* **26**:911-944 (1995); Regoli *et al.*, *Pharmacol. Rev.* **46**(4):551-599 (1994)). The human NK₁ receptor closely resembles the NK₁ receptor of guinea-pigs and gerbils but differs markedly from the NK₁ receptor of rodents. The development of neurokinin antagonists has led to date to a series of peptide compounds of which might be anticipated that they are metabolically too labile to be employed as pharmaceutically active substances (Longmore J. *et al.*, *DN&P* **8**(1):5-23 (1995)). NK₁-antagonists have been studied for a wide variety of indications including emesis, (stress-related) anxiety states, inflammatory responses, smooth muscle contraction and pain perception. NK₁-antagonists are in development for indications such as emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, visceral pain, neurogenic inflammation, asthma, micturition disorders, pancreatitis and nociception.

It has now surprisingly been found that a particular class of compounds with predominantly NK₁-activity reduces to a large extent a number of unwanted side-effects associated with opioid analgesics, thereby increasing the total tolerability of said opioids in pain treatment, in particular in opioid-based acute and chronic pain treatments, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments. More specifically, it was found in opioid-based treatments of pain that emesis was inhibited, respiratory depression was reduced, the tolerance for opioids was prevented and constipation was not worsened. Also, due to the intrinsic antinociceptive activity of NK₁-antagonists, even some increase in opioid efficacy is noted, thereby creating the option to reduce the opioid dose without effecting its analgesic action. Finally, by this combination, psychotropic properties were added to the analgesic efficacy by reducing stress, anxiety and depression.

Background prior art

Neurokinin antagonists are well known in the art (see for an overview e.g. US 5,880,132) and exhibit a variety of non-related chemical structures.

Compounds containing the 1-piperidin-4-yl-piperazinyl moiety were disclosed in WO 97/16440-A1, published May 9, 1997 by Janssen Pharmaceutica N.V. for use as substance P antagonists, in WO 02/32867, published April 25, 2002 by Glaxo Group Ltd. for their special advantages as neurokinin antagonists (more specifically were disclosed 4-piperazin-1-yl-piperidine-1-carboxylic acid amide derivatives), in

-3-

WO 01/30348-A1, published May 03, 2001 by Janssen Pharmaceutica N.V., for use as substance P antagonists for influencing the circadian timing system, and in WO 02/062784-A1, published August 15, 2002 by Hoffmann-La Roche AG for use as NK₁ antagonists.

5

Formulations containing NK₁-antagonists and opioid analgesics for the prevention and/or treatment of pain and/or nociception are disclosed in WO 96/20009 (Merck, July 4, 1996), US 5,880,132 (Merck, March 9, 1999) and WO 97/25988 (Eli Lilly, July 24, 1997). There is no mentioning of the reduction of side-effects apart from emesis.

10

The compounds of the present invention differ from the compounds of the prior art in the substitution of the piperazinyl moiety, being a substituted piperidinyl moiety as well as in their improved ability as potent, orally and centrally active neurokinin antagonists with therapeutic value in combinations with opioid analgesics for reduction of certain opioid-induced side-effects and increasing the tolerability of said opioids.

15


The compounds *per se* are disclosed in our co-pending application WO 2004/033428 A1 (Janssen Pharmaceutica, April 22, 2004) as well as their use as neurokinin antagonists.

20

Description of the Invention

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, a therapeutically effective amount of an opioid analgesic and a compound according to Formula (I)

25



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein :

- n is an integer, equal to 0, 1 or 2 ;
 30 m is an integer, equal to 1 or 2, provided that if m is 2, then n is 1 ;
 p is an integer equal to 1 or 2 ;
 Q is O or NR³ ;
 X is a covalent bond or a bivalent radical of formula -O-, -S- or -NR³- ;

-4-

- each R³ independently from each other, is hydrogen or alkyl ;
 each R¹ independently from each other, is selected from the group of Ar¹,
 Ar¹-alkyl and di(Ar¹)-alkyl ;
- q is an integer equal to 0 or 1 ;
- 5 R² is alkyl, Ar², Ar²-alkyl, Het¹ or Het¹-alkyl ;
- Y is a covalent bond or a bivalent radical of formula -C(=O)- or -SO₂-;
- each Alk represents, independently from each other, a covalent bond; a bivalent
 straight or branched, saturated or unsaturated hydrocarbon radical having
 from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated
 10 hydrocarbon radical having from 3 to 6 carbon atoms ; each radical
 optionally substituted on one or more carbon atoms with one or more
 alkyl, phenyl, halo, cyano, hydroxy, formyl and amino radicals ;
- L is selected from the group of hydrogen, alkyloxy, Ar³-oxy,
 alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(Ar³)amino, Ar³,
 15 Ar³-carbonyl, Het² and Het²-carbonyl;
- Ar¹ is phenyl, optionally substituted with 1, 2 or 3 substituents each
 independently from each other selected from the group of halo, alkyl,
 cyano, aminocarbonyl and alkyloxy ;
- Ar² is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3
 20 substituents, each independently from each other, selected from the group
 of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy,
 alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and
 di(alkyl)aminocarbonyl ;
- Ar³ is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents
 each independently from each other selected from the group of alkyloxy,
 25 alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl,
 imidazo[1,2-a]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino
 and cyano;
- Het¹ is a monocyclic heterocyclic radical selected from the group of pyrrolyl,
 30 pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl,
 isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic
 heterocyclic radical selected from the group of quinolinyl, quinoxalinyl,
 indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,
 benzisothiazolyl, benzofuranyl and benzothienyl ; each monocyclic and
 35 bicyclic heterocyclic radical may optionally be substituted on any atom by a
 radical selected from the group of halo and alkyl ;

-5-

- 5 Het² is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl ; or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromenyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl ; each

 10 monocyclic and bicyclic radical optionally substituted with one or more radicals selected from the group of Ar¹, Ar¹alkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkyloxyalkyl and alkyloxycarbonyl ; and

 15 alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino radicals .

20

- More in particular, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the

 25 stereochemically isomeric forms thereof, the *N*-oxide form thereof and a prodrug thereof, wherein :

- n is 1 ;

 m is 1 ;

 p is 1 ;

 30 Q is O ;

 X is a covalent bond ;

 each R¹ is Ar¹ or Ar¹-alkyl ;

 q is 0 or 1 ;

 R² is Ar² ;



 35 Y is a covalent bond or a bivalent radical of formula -C(=O)- or -SO₂- ;

 each Alk represents, independently from each other, a covalent bond; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having

- from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl, halo, cyano, hydroxy, formyl and amino radicals ;
- 5 L is selected from the group of hydrogen, alkyloxy, Ar³-oxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(Ar³)amino, Ar³ and Het²;
- Ar¹ is phenyl, optionally substituted with 1, 2 or 3 alkyl radicals ;
- Ar² is phenyl, optionally substituted with 1, 2 or 3 alkyl radicals ;
- Ar³ is phenyl, optionally substituted with 1, 2 or 3 substituents each
- 10 independently from each other selected from the group of alkyloxy, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano ;
- Het² is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl,
- 15 isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, chromenyl and benzimidazolyl ; each monocyclic and bicyclic radical optionally substituted with one or more radicals selected from the group of Ar¹, Ar¹alkyl, halo,
- 20 hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo and alkyloxycarbonyl ; and
- alkyl is a straight hydrocarbon radical having 1 to 6 carbon atoms, optionally substituted with one or more halo radicals ;

- More in particular, the invention relates to a pharmaceutical composition
- 25 comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and a prodrug thereof, wherein R¹ is Ar¹methyl and attached to the 2-position or R¹ is Ar¹ and attached
- 30 to the 3-position, as exemplified in either of the following formulas for compounds according to Formula (I) wherein m and n are equal to 1 and Ar is an unsubstituted phenyl. Preferably, Ar¹methyl is an unsubstituted benzyl radical.

-7-



- More in particular, the pharmaceutical composition comprises a compound according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and a prodrug thereof, wherein the $R^2-X-C(=Q)-$ moiety is 3,5-di-
 5 (trifluoromethyl) phenylcarbonyl.

More in particular, the pharmaceutical composition comprises a compound selected from the group of :

- 10 ○ {4-[4-(1-benzoyl-piperidin-4-yl)-piperazin-1-yl]-2-benzyl-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone ; and
 ○ (2-benzyl-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-piperidin-4-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone.

- 15 Most in particular, the pharmaceutical composition comprises a compound according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and a prodrug thereof, with compound number 5, 110, 97, 45, 22, 151, 80, 62, 104, 8, 78, 12,
 20 39, 113, 16, 56, 143, 36, 77, 106, 102, 6, 3, 142, 51, 9, 13, 32, 139, 4, 108, 89, 116, 2, 42, 140, 85, 37, 65, 133, 79, 64, 7, 141, 132, 134, 119, 90, 11, 26, 10 and 144 as cited in the Experimental section.

- In the framework of this application, alkyl is defined as a monovalent straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms, for example
 25 methyl, ethyl, propyl, butyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl, hexyl ; alkyl further defines a monovalent cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, for example cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The definition of alkyl also comprises an alkyl radical that is optionally substituted on one or more carbon atoms with one or more phenyl, halo, cyano, oxo,
 30 hydroxy, formyl and amino radicals, for example hydroxyalkyl, in particular

hydroxymethyl and hydroxyethyl and polyhaloalkyl, in particular difluoromethyl and trifluoromethyl.

5 In the framework of this application, halo is generic to fluoro, chloro, bromo and iodo.

In the framework of this application, with "compounds according to the invention" is meant a compound according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and a prodrug thereof.

10 In the framework of this application, especially in the moiety $\text{Alk}^a\text{-Y-Alk}^b$ in Formula (I), when two or more consecutive elements of said moiety denote a covalent bond, then a single covalent bond is denoted. For example, when Alk^a and Y denote both a covalent bond and Alk^b is CH_2 , then the moiety $\text{Alk}^a\text{-Y-Alk}^b$ denotes $-\text{CH}_2$.

15 The pharmaceutically acceptable salts are defined to comprise the therapeutically active non-toxic acid addition salts forms that the compounds according to the invention are able to form. Said salts can be obtained by treating the base form of the compounds according to the invention with appropriate acids, for example inorganic acids, for
20 example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid ; organic acids, for example acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid,
25 cyclamic acid, salicylic acid, p-aminosalicylic acid and pamoic acid.

The compounds according to the invention containing acidic protons may also be converted into their therapeutically active non-toxic metal or amine addition salts forms by treatment with appropriate organic and inorganic bases. Appropriate base salts forms
30 comprise, for example, the ammonium salts, the alkaline and earth alkaline metal salts, in particular lithium, sodium, potassium, magnesium and calcium salts, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hybramine salts, and salts with amino acids, for example arginine and lysine.

35 Conversely, said salt forms can be converted into the free forms by treatment with an appropriate base or acid.

The term addition salt as used in the framework of this application also comprises the solvates that the compounds according to the invention as well as the salts thereof, are able to form. Such solvates are, for example, hydrates and alcoholates.

5 The *N*-oxide forms of the compounds according to the invention are meant to comprise those compounds according to the invention wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide, particularly those *N*-oxides wherein one or more tertiary nitrogens (e.g. of the piperazinyll or piperidinyl radical) are *N*-oxidized. Such *N*-oxides can easily be obtained by a skilled person without any inventive skills and
10 they are obvious alternatives for the compounds according to the invention since these compounds are metabolites, which are formed by oxidation in the human body upon uptake. As is generally known, oxidation is normally the first step involved in drug metabolism (Textbook of Organic Medicinal and Pharmaceutical Chemistry, 1977, pages 70- 75). As is also generally known, the metabolite form of a compound can also.
15 be administered to a human instead of the compound per se, with much the same effects.

The compounds according to the invention possess at least 2 oxydizable nitrogens (tertiary amines moieties). It is therefore highly likely that *N*-oxides are to form in the human metabolism.

20 The compounds according to Formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material according to Formula (I) with an appropriate organic or inorganic
25 peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid,
30 alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

35 The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms that the compounds according to Formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds

denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-
5 configuration. Compounds encompassing double bonds can have an E or Z- stereochemistry at said double bond. Stereochemically isomeric forms of the compounds according to Formula (I) are obviously intended to be embraced within the scope of this invention.

10 Following CAS nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an *R* or *S* descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [*R**,*R**] or [*R**,*S**], where *R** is always specified as the reference
15 center and [*R**,*R**] indicates centers with the same chirality and [*R**,*S**] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an *S* configuration and the second center is *R*, the stereo descriptor would be specified as *S*-[*R**,*S**]. If “ α ” and “ β ” are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring
20 number, is arbitrarily always in the “ α ” position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric carbon atom in the ring system (hydrogen atom in compounds according to Formula (I)) relative to the position of the highest priority substituent on the reference atom is denominated “ α ”, if it is on the same side of the mean plane determined by the ring
25 system, or “ β ”, if it is on the other side of the mean plane determined by the ring system.


Compounds according to the invention and some of the intermediate compounds have at least two stereogenic centers in their structure, namely at the 2- or 3-position of the piperidinyl-moiety (R and S) and at the 4-position, where the attached radical may
30 be either in the cis or trans position with respect to the radical at the 2- or 3-position on the piperidinyl-moiety.

The invention also comprises pharmaceutical compositions according to the invention comprising derivative compounds (usually called “pro-drugs”) of the
35 pharmacologically-active compounds according to the invention, which are degraded *in vivo* to yield the compounds according to the invention. Pro-drugs are usually (but not always) of lower potency at the target receptor than the compounds to which they are

-11-

degraded. Pro-drugs are particularly useful when the desired compound has chemical or physical properties that make its administration difficult or inefficient. For example, the desired compound may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further
 5 discussion on pro-drugs may be found in Stella, V. J. *et al.*, "Prodrugs", *Drug Delivery Systems*, 1985, pp. 112-176, and *Drugs*, 1985, 29, pp. 455-473.

Pro-drugs forms of the pharmacologically-active compounds according to the invention will generally be compounds according to the invention, having an acid group
 10 which is esterified or amidated. Included in such esterified acid groups are groups of the formula $-\text{COOR}^x$, where R^x is a C_{1-6} alkyl, phenyl, benzyl or one of the following groups
 :



15 Amidated groups include groups of the formula $-\text{CONR}^y\text{R}^z$, wherein R^y is H, C_{1-6} alkyl, phenyl or benzyl and R^z is $-\text{OH}$, H, C_{1-6} alkyl, phenyl or benzyl. Compounds according to the invention having an amino group may be derivatised with a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base will hydrolyze with first order kinetics in aqueous solution.

20

The compounds according to Formula (I) as prepared in the processes described below may be synthesized in the form of racemic mixtures of enantiomers that can be separated from one another following art-known resolution procedures. The racemic compounds according to Formula (I) may be converted into the corresponding
 25 diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated there from by alkali. An alternative manner of separating the enantiomeric forms of the compounds according to Formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically
 30 isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound would

-12-

be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

In the framework of this application, the term opioid means opium-like or morphine-like in terms of pharmacological action. The broad group of opium alkaloids, synthetic derivatives related to the opium alkaloids, and the many naturally occurring and synthetic peptides with morphine-like pharmacological effects is called opioids. In addition to having pharmacological effects similar to those of morphine, a compound must be antagonized by an opioid antagonist such as naloxone to be classified as an opioid. The neuronally located proteins to which opioid agents bind to initiate a biological response are called opioid receptors. Opioids can act peripherally and centrally.

Suitable opioids or opioid analgesics for use in the present invention include one or more compounds selected from the group of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil and sufentanil; and pharmaceutical acceptable salts and derivatives thereof.

Because of their widespread use as analgesics, preferred opioid analgesics of use in the present invention are one or more compounds selected from the group of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and derivatives thereof.

Suitable pharmaceutically acceptable salts of the opioid analgesics of use in the present invention include those salts described above in relation to the salts of the NK₁-antagonist.

Preferred salts of opioid analgesics of use in the present invention include alfentanil hydrochloride, buprenorphine hydrochloride, butorphanol tartrate, codeine phosphate, codeine sulphate, diacetylmorphine hydrochloride, dihydrocodeine bitartrate, fentanyl citrate, hydrocodone bitartrate, hydromorphone hydrochloride, levorphanol tartrate, meperidine hydrochloride, methadone hydrochloride, morphine sulphate, morphine hydrochloride, morphine tartrate, nalbuphine hydrochloride, oxymorphone hydrochloride, pentazocine hydrochloride, propoxyphene hydrochloride and propoxyphene napsylate (2-naphthalene sulphonic acid (1:1) monohydrate).

-13-

Particular preferred opioid analgesics of use in the present invention are morphine, fentanyl and pharmaceutical acceptable salts and derivatives thereof.

- 5 More particular preferred opioid analgesics of use in the present invention are morphine sulphate and fentanyl citrate.

Pharmacology

10 The compounds according to the invention are potent inhibitors of neurokinin-mediated effects, in particular those mediated via the NK₁ receptor, and may therefore be described as neurokinin antagonists, especially as substance P antagonists, as indicated *in vitro* by the antagonism of substance P-induced relaxation of pig coronary arteries which is described hereinafter. The binding affinity of the present compounds for the human, guinea-pig and gerbil neurokinin receptors may be determined *in vitro* in
15 a receptor binding test using ³H-substance-P as radioligand. The subject compounds also show substance-P antagonistic activity *in vivo* as may be evidenced by, for instance, the antagonism of substance P-induced plasma extravasation in guinea-pigs, or the antagonism of drug-induced emesis in ferrets (Watson *et al.*, *Br. J. Pharmacol.* **115**:84-94 (1995)).

20 The combination of an opioid analgesic with an NK₁ antagonist results in improved efficacy. Additional to the gain in efficacy, this combination also reduces several of the side-effects currently present with clinically used opioids. NK₁ receptor antagonists potentiating the analgesic activity of opioids require lower doses, resulting in
25 a reduced risk of opioid side-effects, in particular emesis, respiratory depression and tolerance. But additionally it's seen that at similar doses (not lower opioid doses) there are also benefits of adding NK1 to opioid.

30 Respiratory depression is the most serious side effect of opioid analgesics and is the primal cause of death from overdose. Opioids decrease the sensitivity of chemoreceptors in the brainstem to carbon dioxide, a normal stimulus of ventilatory reflexes. The result is a blunting of the ventilatory response to increases in the carbon dioxide tension (P_{CO₂}) in blood and cerebrospinal fluid. At equally effective analgesic doses, most opioids produce a similar degree of respiratory depression, as shown by an
35 elevation in the blood P_{CO₂}. This effect is at least additive to that produced by other drugs that depress CNS functions, including general anesthetics and sedative-hypnotics. The mild respiratory depression produced by therapeutic doses of opioids is normally of

-14-

little consequence. However, opioid analgesics must be used cautiously in patients with traumatic head injuries, with emphysema and who are morbidly obese.

At three to five times its usual analgesic dose, morphine can cause respiratory arrest in the nontolerant patient. In contrast, much higher doses will have minimal respiratory effects in morphine-tolerant individuals.

Tolerance refers to a reduced drug effect with repeated use and/or a need for higher doses to produce the same effect. Because tolerance does not occur to the same extent for all effects, drug abusers who take increasing amounts of drugs risk exposure to those effects to which tolerance does not develop. Tolerance develops to many of the effects of opioids. With repeated drug administration, larger doses are necessary to produce the same pharmacological response. The rate of tolerance development varies with the affected tissue or organ. Tolerance develops rapidly to the antiemetic effects of opioids; more gradually to their analgesic, endocrine and respiratory depressant effects; and virtually not at all to their constipating and miotic effects.

The compounds according to the invention have shown to reduce unwanted side-effects induced by opioids. Such reduction can be tested by *in vivo* testing using several species (e.g. ferrets, gerbils, rats, guinea pigs) and several pain models, covering pain models aiming at different states of acute and chronic pain, as well as animal models aiming to profile opioid side effects (such as opioid-induced emesis, GI transit and respiratory depression). For instance, the compounds of the present invention :

- were able to inhibit the opioid-induced emesis in several species;
 - did not reduce the antinociceptive properties of opioids in models of acute, visceral and high intensity pain;
 - had an additive effect on the antinociceptive properties of opioids in models of inflammatory and chronic neuropathic pain;
 - reduced the respiratory depression induced by opioids in several species;
 - were able to reduce and overcome the tolerance observed with opioids daily administered in a model of chronic neuropathic pain;
 - did not interfere with the discriminative central narcotic effects of opioids;
 - had no effect on the pharmacokinetics of opioids when administered concomitantly.
- This excludes pharmacokinetic interactions as the origin of the pharmacological effects observed.

The present invention therefore also relates to the use of a pharmaceutical composition according to the invention for the manufacture of a medicament for the

prevention and/or treatment of pain and/or nociception.

In particular, the present invention relates to the use of a pharmaceutical composition according to the invention for the manufacture of a medicament for the
5 opioid-based prevention and/or treatment of acute and chronic pain, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments.

The present invention further relates to the use of a pharmaceutical composition
10 according to the invention for the manufacture of a medicament for the prevention and/or treatment of emesis in opioid-based treatments of pain.

The present invention further relates to the use of a pharmaceutical composition according to the invention for the manufacture of a medicament for the prevention
15 and/or treatment of emesis in opioid-based treatments of pain, wherein the emesis is nausea and vomiting.

The present invention also relates to the use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist according to Formula (I), the pharmaceutically
20 acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for the manufacture of a medicament for the prevention and/or treatment of respiratory depression in opioid-based treatments of pain.

The present invention also relates to the use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist according to Formula (I), the pharmaceutically
25 acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for the manufacture of a medicament for reducing and/or overcoming the tolerance observed with opioids, e.g.
30 when daily administered in chronic neuropathic pain.

To prepare the pharmaceutical compositions of this invention, an effective amount of the active ingredient, optionally in addition salt form, is combined in intimate
admixture with a pharmaceutically acceptable carrier, which carrier may take a wide
35 variety of forms depending on the form of preparation desired for administration. The pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by

inhalation. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Other compositions may be compositions in a form suitable for sublingual, intranasal or pulmonary application or suitable as eye droplets.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

Since the compounds according to the invention are potent orally administrable NK₁ antagonists, pharmaceutical compositions comprising said compounds for administration orally are especially advantageous.

-17-

The NK₁-receptor antagonist and the opioid analgesic may be formulated in a single pharmaceutical product or composition or alternatively in individual pharmaceutical products or compositions for simultaneous, separate or sequential use in accordance with the present invention. The pharmaceutical product or composition may
5 also be a product comprising the NK₁-receptor antagonist and the opioid analgesic as separate unit dosages.

When administered in combination, either as a single or as separate pharmaceutical composition(s), the NK₁-receptor antagonist and the opioid analgesic are presented in a
10 ratio which is consistent with the manifestation of the desired effect. In particular, the ratio by weight of the NK₁-antagonist to the opioid analgesic will suitably be approximately 1 to 1. Preferably, this ratio will be between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1.

15 A suitable dosage level for the NK₁-receptor antagonist is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg day. The compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day.

20 The opioid analgesic may be administered at a dosage level up to conventional dosage levels for such analgesics, but preferably at a reduced level in accordance with the present invention. Suitable dosage levels will depend upon the analgesic effect of the chosen opioid analgesic, but typically suitable levels will be about 0.001 to 25 mg/kg per day, preferably 0.005 to 10 mg/kg per day, and especially 0.005 to 5 mg/kg
25 day. The compound may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day.


It will be appreciated that the amount of an NK₁-receptor antagonist and an opioid analgesic required for use in the prevention and/or treatment of pain and nociception
30 will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the human in need of such a treatment, and will ultimately be at the discretion of the attendant physician.

35 Preparation

The compounds according to the invention can generally be prepared by a succession of steps, each of which is known to the skilled person.

The compounds of Formula (I) are conveniently prepared by reductively *N*-alkylating an intermediate of Formula (II) wherein R^1 , R^2 , X , Q , m , n and p are defined as in Formula (I), with a *N*-substituted piperidinon of Formula (III) wherein R^1 , Alk, Y, L and q are defined as in Formula (I). Said reductive *N*-alkylation may be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol or toluene or a mixture thereof, and in the presence of an appropriate reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. In case a borohydride is used as a reducing agent, it may be convenient to use a complex-forming agent such as, for example, titanium(IV)-isopropylate as described in J. Org. Chem, 1990, 55, 2552-2554. Using said complex-forming agent may also result in an improved *cis/trans* ratio in favor of the *trans* isomer. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal.

In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. Stirring and optionally elevated temperatures and/or pressure may enhance the rate of the reaction.




In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, titration and chromatography.

Especially advantage is the preparation of a compound according to the invention according to the previous reaction scheme in which the Alk-Y-Alk-L-moiety is benzyl, thus giving rise to a compound according to Formula (I) in which the Alk-Y-Alk-L-moiety is benzyl. Said compound is pharmacological active and can be converted into a compound according to the invention in which the Alk-Y-Alk-L-moiety is hydrogen by

-19-

reductive hydrogenation using e.g. hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal. The resulting compound according to the invention can then be converted into other compounds according to the invention by art-known transformations, e.g. acylation and alkylation.


In particular, the compounds of Formula (I^a) can be prepared by reacting a final compound of Formula (I') wherein R¹, R², X, Q, m, n, p and q are defined as in Formula (I) with an acyl compound of Formula (V) wherein Alk and L are defined as in Formula (I) and W¹ is an appropriate leaving group such as, for example, a halo, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.



Alternatively, the compounds of Formula (I^a) can also be prepared by reacting a final compound of Formula (I') wherein R¹, R², X, Q, m, n, p and q are defined as in Formula (I) with a carboxylic acid of Formula (VI) wherein Alk and L are defined as in Formula (I)(base-catalyzed nucleophilic addition reaction). The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried at a temperature ranging between room temperature and reflux temperature.


30

-20-




The above reaction may also be carried out under equivalent conditions with the carboxylic ester of the carboxylic acid of Formula (VI).

- 5 In particular, the compounds of Formula (I^b) can be prepared by reacting a final compound of Formula (I') wherein R¹, R², X, Q, m, n, p and q are defined as in Formula (I) with a keto-compound of Formula (VII) wherein W² is an appropriate leaving group such as, for example, a halogen, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried at a temperature ranging between room temperature and reflux temperature.




- The compounds of Formula (I^c) can be prepared by reductive amination/alkylation of a final compound of Formula (I') wherein R¹, R², X, Q, m, n, p and q are defined as in Formula (I) with a compound of Formula (VIII) wherein Alk and L are defined as in Formula (I) and W³ is an appropriate leaving group such as, for example, a halogen, e.g. chloro or bromo, or a sulfonyloxy leaving group, e.g. methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, a chlorinated hydrocarbon, e.g. dichloromethane, an alcohol, e.g. ethanol, or a ketone, e.g. methyl isobutylketone, and in the presence of a suitable base such as, for example, sodium carbonate, sodium hydrogen carbonate or triethylamine.

Stirring may enhance the rate of the reaction. The reaction may conveniently be carried at a temperature ranging between room temperature and reflux temperature.



5 The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediates of formula (II) may be prepared by reductively *N*-alkylating an intermediate of formula (IX) with an intermediate of formula (X) in which W⁴ is a benzyl radical, after which the compound
10 according to Formula (X) is subsequently reduced to yield an intermediate compound according to Formula (II). Said reductive *N*-alkylation may be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of an appropriate reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy
15 borohydride. In case a borohydride is used as a reducing agent, it may be convenient to use a complex-forming agent such as, for example, titanium(IV)isopropylate as described in J. Org. Chem, 1990, 55, 2552-2554. Using said complex-forming agent may also result in an improved *cis/trans* ratio in favor of the *trans* isomer. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable
20 catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-
25 poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. Stirring and optionally elevated temperatures and/or pressure may enhance the rate of the reaction.



The preparation of these and other intermediates is described in WO 97/16440-A1, published May 9, 1997 by Janssen Pharmaceutica N.V, which is disclosed herein by reference as well as in other publications mentioned in WO 97/16440-A1, such as , e.g. EP-0,532,456-A and in our co-pending application WO 2004/033428 A1.

The following examples are intended to illustrate and not to limit the scope of the present invention.


10 Experimental Section

Hereinafter "RT" means room temperature, "CDI" means 1,1'-carbonyldiimidazole, "DIPE" means diisopropylether, "MIK" means methyl isobutyl keton, "BINAP" means [1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine], "NMP" means 1-methyl-2-pyrrolidinone, "Pd₂(dba)₃" means tris(dibenzylideneacetone)dipalladium and "DMF" means *N,N*-dimethylformamide.

Preparation of the intermediate compounds

Example A1

a. Preparation of intermediate compound 1




Et₃N (0.55 mol) was added to a stirring mixture of 7-(phenylmethyl)-1,4-dioxo-8-azaspiro[4.5]decane (0.5 mol) in toluene (1500 ml). 3,5-Bis(trifluoromethyl)benzoyl chloride (0.5 mol) was added over a 1-hour period (exothermic reaction). The mixture was stirred at room temperature for 2 hours, then allowed to stand for the weekend and washed three times with water (500ml, 2x250ml). The organic layer was separated, dried, filtered and the solvent was evaporated. Yielding: 245g (100%). Part of this

-23-

fraction was crystallized from petroleum ether. The precipitate was filtered off and dried. Yielding: 1.06g of intermediate compound 1.


**b. Preparation of
intermediate compound 2**



5 HCl cp (300 ml) was added to a mixture of intermediate compound 1 (0.5 mol) in ethanol (300 ml) and H₂O (300 ml). The reaction mixture was stirred at 60 °C for 20 hours. The precipitate was filtered off, ground, stirred in H₂O, filtered off, washed with petroleum ether and dried. Yielding: 192 g of intermediate compound 2 ((+)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone) (89.4%) (mixture of R and S enantiomers).

10

**c. Preparation of
intermediate compound 3**




A mixture of intermediate compound 2 (0.046 mol), 1-(phenylmethyl)piperazine (0.051 mol) and C (0.056 mol) was stirred for 2 hours at 40 °C. The reaction mixture was cooled to room temperature. Ethanol, p.a. (350 ml) was added. BH₄Na (0.138 mol) was added. The resulting reaction mixture was stirred for one hour at room temperature, then for one hour at 50 °C. More BH₄Na (5.2 g) was added and the reaction mixture was stirred for 2 hours at 50 °C. Again, BH₄Na was added and the reaction mixture was stirred overnight at room temperature, then for 2 hours at 50 °C. Water (10 ml) was added. The mixture was stirred for 15 min. CH₂Cl₂ (200 ml) was added and the mixture was stirred for 15 min. The organic phase was separated, dried (MgSO₄), dicalite was added, the mixture was filtered over dicalite, and the filtrate was evaporated. This fraction was separated into (CIS) and (TRANS) by column chromatography over silica gel. The desired (TRANS)-fractions were collected and the solvent was evaporated,

-24-


- giving 14.8 g of residue ((I), 1.06 % (CIS)) and 4.9 g of residue ((II), 6 % (CIS)). Resolution and purification of those (TRANS)-fractions (± 20 g in total) was obtained by chromatography over stationary phase Chiralcel OD (1900Gr) in Prochrom LC110 35 bar (eluent: hexane/ethanol 90/10). The desired fractions were collected and the solvent was evaporated. Yielding: 9.5 g of intermediate compound 3 (2R-trans)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]-piperidine.

d. Preparation of intermediate compound 4



- A mixture of intermediate compound 3 (0.288 mol) in methanol (700 ml) was hydrogenated at 40 °C with Pd/C, 10 % (5 g) as a catalyst. After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. Yielding: 141.2 g of intermediate compound 4 (+)-(2R-trans)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(1-piperazinyl)piperidine.

- Example A2
Preparation of intermediate compound 5




A mixture of *N*-[(1,1-dimethylethoxy)carbonyl]-L-tyrosine 1,1-dimethylcarbonate (0.005 mol), *N,N*-dimethyl-4-pyridinamine (0.006 mol) and Et₃N (0.006 mol) in CH₂Cl₂, p.a. (10 ml) was stirred at room temperature. *N*-(ethylcarbonimidoyl)-*N,N*-dimethyl-1,3-

-25-

- propanediamine monohydrochloride (0.006 mol) was added portionwise and was stirred for 45 minutes at room temperature. Then final compound 2 (described in example B1.b) (0.005 mol) was added and the reaction mixture was stirred overnight at room temperature. The mixture was washed with H₂O and Na₂CO₃. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/MeOH 100/0;98/2;96/4;94/6). The purest fractions were collected and the solvent was evaporated Yield : 1.4 g intermediate compound 5 (30 %).


10 Example A3

a. Preparation of intermediate compound 6



- A mixture of 7-(hydroxyphenylmethyl)-1,4-dioxaspiro[4,5]decane-8-carboxylic acid 1,1-dimethylethyl ester (0.5 mol) and 2-methyl-2-propanol potassium salt (6 g) in toluene (900 ml) was stirred and refluxed for 2 hours. The mixture was evaporated and the residue was stirred up in petrol ether and a little water. The mixture was decanted and the residue was stirred up in DIPE. The precipitate was filtered off and dried. Yielding : 127.4 g of intermediate compound 6 (92 %).


b. Preparation of intermediate compound 7



- A mixture of intermediate compound 6 (0.5 mol) in methanol (700 ml) was hydrogenated at 50 °C overnight with Pd/C, 10 % (5 g) as a catalyst. After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was taken up in water and extracted with CH₂Cl₂. The organic layer was dried (MgSO₄), filtered off and evaporated. Yielding : 99 g intermediate compound 7 (85 %).


-26-

c. Preparation of
intermediate compound 8




- Et₃N (0.55 mol) was added to a mixture of intermediate compound 7 (0.5 mol) in toluene (1500 ml). 3,5-Dimethylbenzoyl chloride (0.5 mol) was added dropwise slowly over a 1-hour period while the temperature was kept below 50 °C and while stirring was continued. The mixture was stirred at room temperature overnight, then washed three times with water (500 ml, 2x250 ml) and separated into its layers. The organic layer was dried (MgSO₄), filtered and the solvent was evaporated. Yielding: 197 g (113 %). Part of this fraction was dried. Yielding: 0.65 g of intermediate compound 8.

d. Preparation of
intermediate compound 9



- A mixture of intermediate compound 8 (0.56 mol) in ethanol (300 ml), HCl (300 ml) and H₂O (300 ml) was stirred at 60 °C for 8 hours. The mixture was stirred at room temperature for the weekend. The precipitate was filtered off, taken up in water, filtered off, washed with petroleum ether and dried. Yielding: 140.9 g of intermediate compound 9 (88 %).

e. Preparation of
intermediate compound 10




- A mixture of intermediate compound 9 (0.05 mol) and 1-(phenylmethyl)-piperazine (0.05 mol) in thiophene, 4 % solution (2 ml) and toluene (500 ml) was hydrogenated with Pd/C, 10 % (1 g) as a catalyst. After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography

-27-


over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 99/1). The pure fractions were collected and evaporated. Yielding : 17.07 g (71 %). The pure fractions of fraction 1 were collected and evaporated. Yielding : 2.5 g of intermediate compound 10 (10 %).

f. Preparation of
intermediate compound 11




- 5 A mixture of intermediate compound 10 (0.0052 mol) in methanol (100 ml) was hydrogenated at 50 °C for one night with Pd/C, 10 % (1 g) as a catalyst. After uptake of H_2 (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was purified on a glass filter over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 99/1, 98/2, 97/3, 96/4 and 95/5). The pure fractions were collected and evaporated. Yielding : 1.7 g on
- 10 intermediate compound 11 (83 %).

Example A4
Preparation of intermediate
compound 12




- A mixture of final compound 2 (prepared according to B1b) (0.01 mol) and KOH (0.15 mol) in 2-propanol (50 ml) was stirred and refluxed for 18 hours. The solvent was
- 15 evaporated, then the residue was taken up in H_2O (20 ml) and the mixture was extracted with CH_2Cl_2 . The organic layer was washed with NaOH (1 N), dried (MgSO_4), filtered and the solvent was evaporated. Yield: 3.25 g of intermediate compound 12 (95 %).

-28-


Preparation of the final compoundsExample B1a. Preparation of final compound 1

A mixture of intermediate compound 4 (0.12 mol) and 1-(phenylmethyl)-4-piperidinone (0.12 mol) in methanol (250 ml) was hydrogenated (H163-066) at 50 °C with Pd/C 10 % (3 g) as a catalyst in the presence of thiophene solution (2 ml). After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was suspended in petroleum ether, filtered off and crystallized from DIPE. Yield : 46 g (F1). The filtrate was evaporated. Yield : 37.7 g (F2). F1 and F2 were combined and purified by column chromatography over silica gel (eluent : CH₂Cl₂/MeOH 91/9). The product fractions were collected and the solvent was evaporated. Yield : 46 g (F3). F3 was crystallized from DIPE. Yield : 0.65 g of final compound 1.


b. Preparation of final compound 2

A mixture of final compound 1 (0.0074 mol) in methanol (150 ml) was hydrogenated (H163-077) with Pd/C 10 % (1 g) as a catalyst. After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was concentrated. Yield : 4.3 g of final compound 2.

-29-

Example B2Preparation of final
compound 3

A mixture of compound 2 (0.0015 mol) and Et₃N (0.1 mol) in CH₂Cl₂ (100 ml) was stirred at room temperature. Benzoylchloride (0.0025 mol) was dissolved in CH₂Cl₂ and added dropwise to the reaction mixture. The mixture was stirred for 1 hour at room temperature. NaOH (1 N; 100 ml) was added and the mixture was stirred for 30 minutes at room temperature. The separated aqueous layer was extracted with CH₂Cl₂. The organic layer was washed with H₂O, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/MeOH 100/0;90/10). The desired fractions were collected and the solvent was evaporated. Yield : 0.624 g of final compound 3. (61 %).

Example B3a. Preparation of final
compound 4


A mixture of 5-methyl-4-isoxazolecarboxylic acid (0.0015 mol) in CH₂Cl₂ (20 ml) and 1,1'-carbonylbis-1*H*-imidazole (0.0015 mol) was stirred for 2 hours at room temperature. Compound 2 (prepared according to B1.b) (0.001 mol) was added. After stirring overnight, the reaction mixture was washed with diluted NaOH, washed with H₂O, dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂ -gradient 0->10 % MeOH). The

-30-

product fractions were collected and the solvent evaporated. The residue was dried.


Yield : 0.204 g of final compound 4.

b. Preparation of final compound 5




5 A mixture of 3-thiophenecarboxylic acid (0.00188 mol), *N,N*-dimethyl-4-pyridinamine (0.00255 mol) and Et₃N (0.00255 mol) in CH₂Cl₂ (200 ml) was stirred at room temperature. *N,N*-dimethyl-*N'*-(methylcarbonimidoyl)-1,3-propanediamine (0.00255 mol) was added portionwise and the mixture was stirred for one hour at room temperature. A solution of compound 2 (prepared according to B1b) (0.00188 mol) in CH₂Cl₂ was added dropwise and the reaction mixture was stirred over the weekend at
10 room temperature. The mixture was poured out into 1 g NaOH/water. The layers were separated. The water layer was extracted with CH₂Cl₂. The separated organic layer was dried (MgSO₄), filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH from 100/0 to 90/10). The product fractions were collected and the solvent was evaporated. Yield: 0.749 g of
15 compound 5 (58 %).

-31-

Example B4a. Preparation of final compound 6


- A mixture of compound 2 (prepared according to B1b) (0.005 mol), 4-(chlorophenyl-acetyl)-morpholine (0.005 mol) and Na_2CO_3 (0.01 mol) in MIK, p.a. (125 ml) was stirred and refluxed for 18 hours using a water separator. The reaction mixture was washed with water, dried, filtered and the solvent evaporated. The residue was purified over silica gel on a glass filter (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The product fractions were collected and the solvent was evaporated. The residue was suspended in DIPE, filtered off and dried. Yield: 1.702 g of compound 6.

b. Preparation of final compound 7

- A mixture of compound 2 (prepared according to B1b) (0.0012 mol), 2-(chloromethyl)-1*H*-benzimidazole (0.0014 mol) and K_2CO_3 (0.0018 mol) in CH_3CN (5ml) was stirred and refluxed for 12 hours, then cooled to room temperature and the solvent was evaporated. The residue was taken up in CH_2Cl_2 . The organic layer was washed with H_2O , dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.95 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 90/10/0.5; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.14 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yielding: 0.087 g of compound 7 (10 %) (mp. 135 °C).

-32-

c. Preparation of final compound 8




A mixture of compound 2 (prepared according to B1b) (0.005 mol) and 2-(chloromethyl)-6-methyl-3-pyridinol (0.006 mol) was taken up in DMF (50 ml). *N*-methyl-*N*-(1-methylethyl)-propanamine (0.02 mol) was added. The reaction mixture was stirred overnight at $\pm 65^{\circ}\text{C}$. The solvent was evaporated. The residue was taken up in CH_2Cl_2 and washed with a diluted NH_3 solution. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{MeOH}/\text{NH}_3)$ 95/5). The desired fractions were collected and the solvent was evaporated. The residue was suspended in DIPE. The precipitate was filtered off and dried. Yield : 1.423 g of compound 8.

10

Example B5


Preparation of final compound 9




A mixture of compound 2 (prepared according to B1b) (0.003 mol) and 1-methyl-1*H*-pyrrole-2-carboxaldehyde (0.0046 mol) was hydrogenated at 50°C under H_2 with Pd/C 10% (1 g) as a catalyst in the presence of thiophene solution (1 ml). After uptake of H_2 (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{MeOH}/\text{NH}_3)$ 97/3;95/5). The product fractions were collected and the solvent was evaporated. The residue was suspended in petroleumether. Yield : 1.079 g of compound 9.

15

-33-


Example B6**Preparation of final
compound 10 and 11**[2 α ,4 α (2R*,4S*)]= compound 10[2 α ,4 β (2R*,4S*)]=compound 11

A mixture of intermediate compound 2 (prepared according to A1b) (0.005 mol), intermediate compound 11 (prepared according to A3f) (0.005 mol) and Ti(OiPr)₄ (3 g) in methanol (150 ml) was hydrogenated at 50 °C under N₂ flow with Pd/C 10 % (1 g) as a catalyst in the presence of thiophene solution (1 ml). After uptake of H₂ (1 eq), the catalyst was filtered off and the filtrate was evaporated. The residue was taken up in H₂O and CH₂Cl₂. The mixture was stirred for 10 min and filtered over dicalite. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 97/3). Two fractions were collected and their solvents were evaporated. Yielding: 0.53 g compound 10 and 0.4 g of compound 11.


Example B7**Preparation of final
compound 12**

A mixture of compound 2 (prepared according to B1b) (0.001 mol) in CH₂Cl₂ (50 ml) and C (0.0015 mol) was stirred overnight. The reaction mixture was washed with diluted NaOH, washed with H₂O, dried and the solvent was evaporated. The residue was purified by column chromatography over silica gel (Eluent: CH₂Cl₂/CH₃OH 100/0 and 90/10). The product fractions were collected and the solvent evaporated. Yield : 0.645 g of compound 12.

-34-


Example B8Preparation of finalcompound 13

A mixture of intermediate compound 12 (prepared according to A4) (0.0015 mol) in HCl/2-propanol (5 ml) and methanol (20 ml) was stirred and refluxed for 1 hour. The reaction mixture was crystallized, filtered off and dried. Yield : 0.43 g of final compound 13 (38 %)

Example B9Preparation of finalcompound 40


A mixture of final compound 31 (prepared according to B2)(0.065 mmol), 4-pyridinyl-boronic acid (0.09 mmol), Pd(OAc)₂ (0.015 mmol), 1,3-bis(diphenylphosphino)propane (0.03 mmol), Na₂CO₃, 2M (1 ml) and DME (2 ml) was stirred at 100 °C for 16 hours. The solvent was evaporated and the residue was taken up in H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried with MgSO₄ and the solvent evaporated. The residue was purified by column chromatography over kromasil (gradient: CH₂Cl₂/CH₃OH 95/5). The desired fractions were collected and the solvent was evaporated. Yield: 1 mg of final compound 40.

-35-

Example B10Preparation of final
compound 85

A mixture of final compound 83 (prepared according to B2)(0.0004 mol), pyrrolidine (0.0006 mol), $\text{Pd}_2(\text{dba})_3$ (0.00001 mol), BINAP (0.00003 mol) and 2-methyl-2-propanol sodium salt (0.0006 mol) in toluene (5 ml) was stirred at 100 °C for 16 hours. The solvent was evaporated and the residue was taken up in H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried with MgSO_4 and the solvent evaporated. The residue was purified by column chromatography over kromasil (gradient: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 95/5). The desired fractions were collected and the solvent was evaporated. Yield: 0.119 g of final compound 85.

10

Example B11Preparation of final
compound 43

A mixture of final compound 31 (prepared according to B2)(0.065 mmol), imidazo(1,2-a)pyridine (0.09 mmol), $\text{Pd}(\text{OAc})_2$ (0.015 mmol), 1,3-bis(diphenylphosphino)propane (0.03 mmol) and Cs_2CO_3 (0.09 mmol) in NMP (5 ml) was stirred at 140 °C for 16 hours. The solvent was evaporated and the residue was taken up in H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried with MgSO_4 and the solvent evaporated. The residue was purified by column chromatography over kromasil


15

-36-

(gradient: CH₂Cl₂/CH₃OH 95/5). The desired fractions were collected and the solvent was evaporated. The desired fractions were collected and the solvent was evaporated. Yield: 8 mg of final compound 43.

5 Example B12


Preparation of final
compound 44




A mixture of compound 31 (prepared according to B2)(0.065 mmol), morpholine (0.2 mmol), Pd(OAc)₂ (0.015 mmol) and 1,3-bis(diphenylphosphino)propane (0.03 mmol) in diglyme (3 ml) under 1 atmosphere CO was stirred at 150 °C for 16 hours. The solvent was evaporated and the residue was taken up in H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried with MgSO₄ and the solvent evaporated. The residue was purified by column chromatography over kromasil (gradient: CH₂Cl₂/CH₃OH 95/5). The desired fractions were collected and the solvent was evaporated. The desired fractions were collected and the solvent was evaporated. Yield: 3 mg of final compound 44.

15

-37-


Example B13**Preparation of final
compound 144**

- 5 A mixture of 4-[(4-acetyloxy)methyl]-1,2,3-thiadiazole-5-carboxylic acid methyl ester (0.001 mol), final compound 2 (prepared according to B1b) (0.002 mol), NaCN (20 mg) in methanol (20ml) was stirred and refluxed for 20 hours. The solvent was evaporated and the residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{MeOH}$ from 100/0 to 80/20). The desired fractions were collected and the solvent was evaporated. The residue was suspended in petroleum ether. The precipitate was filtered off and dried. Yield : 0.110 g of final compound 144.

10 Example B14**Preparation of final
compound 130**


- 15 A mixture of final compound 2 (prepared according to B1b) (0.001 mol), glycolaldehyde dimer (0.001 mol) and 3-thiophene boronic acid (0.001 mol) in 2,2,2-trifluoroethanol (5 ml) was stirred at room temperature for 18 hours. This was followed by addition of a solution of K_2CO_3 (10 %) and extraction with ethyl acetate. The combined organic layers were dried (MgSO_4), filtered and concentrated under vacuum. The residue (0.6 g) was purified by chromatography on a silicagel column ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 92/08/0.2) and the product fractions were concentrated, providing 0.29 g (47 %) of final compound 130.

-38-









Example B15Preparation of final
compound 153







- A mixture of intermediate compound 12 (prepared according to A4) (0.00934 mol) and Et_3N (0.02 mol) in CH_2Cl_2 (200 ml) was stirred on an ice bath, then a solution of 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (0.00943 mol) in CH_2Cl_2 (20 ml) was
- 5 added dropwise over 15 minutes at 0 °C. The reaction mixture allowed to reach room temperature and was stirred for 1 hour at room temperature, NaOH (20 ml) was added and the reaction mixture was stirred for 15 minutes at room temperature. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 . The organic layer was washed with H_2O , dried (MgSO_4), filtered off and the solvent was evaporated. The
- 10 residue was purified by column chromatography over silicagel (eluent : $\text{CH}_2\text{Cl}_2/\text{MeOH}/(\text{MeOH}/\text{NH}_3)$ from 100/0/0 to 90/10/0 to 90/10/0). Two product fractions were collected and each solvent was evaporated. Yield fraction 1: 1.260 g of final compound 153 (22 %).
- 15 The compounds exemplified in the following Tables 1-5 were prepared in a manner analogous to one of the foregoing examples B1 to B15.










Table I













Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
2	B1b	cb	cb	cb	H	2R-trans
121	B1b	cb	cb	cb	H	2R-cis
122	B1b	cb	cb	cb	H	2S-trans
123	B1b	cb	cb	cb	H	2S-cis
15	B4b	cb	cb	cb		2R-trans
16	B4a	cb	cb	cb		2R-trans
17	B4c	cb	cb	cb		2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
18	B4c	cb	cb	cb		2R-trans
124	B4c	cb	cb	cb		2R-trans
9	B5	-CH ₂ -	cb	cb		2R-trans
20	B4b	-CH ₂ -	cb	cb		2R-trans
8	B4c	-CH ₂ -	cb	cb		2R-trans
7	B4b	-CH ₂ -	cb	cb		2R-trans
21	B4b	-CH ₂ -	cb	cb		B-trans
125	B1a	-CH ₂ -	cb	cb		2R-cis







Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
126	B1a	-CH ₂ -	cb	cb		2S-cis
1	B1a	-CH ₂ -	cb	cb		2R-trans
127	B1a	-CH ₂ -	cb	cb		2S-trans
22	B4b	-CH ₂ -	cb	cb		2R-trans
23	B4b	-CH ₂ -	cb	cb		2R-trans
24	B4b	-CH ₂ -	cb	cb		2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^p	L	Physical data
25	B4b	-CH ₂ -	cb	cb		B-trans
26	B4b	-CH ₂ -	cb	cb		B-trans
27	B4b	-CH ₂ - CH=CH-	cb	cb		[2B-[2α,4β(E)]]
128	B14		cb	cb		2R-trans
129	B14		cb	cb		2R-trans
130	B14		cb	cb		2R-trans






Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
131	B14		cb	cb		2R-trans
28	B4c		cb	cb		B-trans
29	B2	cb	C=O	cb		2R-trans
162	B3b	cb	C=O	cb		2R-trans
30	B2	cb	C=O	cb		2R-trans
3	B2	cb	C=O	cb		2R-trans mp. 142.5°C
132	B2	cb	C=O	cb		2S-trans
133	B2	cb	C=O	cb		2R-cis






Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
134	B2	cb	C=O	cb		2S-cis
31	B2	cb	C=O	cb		2R-trans
32	B2	cb	C=O	cb		2R-trans
165	B2	cb	C=O	cb		2R-trans
33	B2	cb	C=O	cb		2R-trans
34	B2	cb	C=O	cb		2R-trans
164	B2	cb	C=O	cb		2R-trans







Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
35	B3b	cb	C=O	cb		2R-trans
36	B2	cb	C=O	cb		2R-trans
163	B2	cb	C=O	cb		2R-trans
37	B2	cb	C=O	cb		2R-trans
135	B2	cb	C=O	cb		2R-trans HCl(1:2)
38	B2	cb	C=O	cb		2R-trans
39	B3a	cb	C=O	cb		2R-trans









Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
40	B9	cb	C=O	cb		2R-trans
41	B10	cb	C=O	cb		2R-trans
42	B10	cb	C=O	cb		2R-trans
43	B11	cb	C=O	cb		2R-trans
44	B12	cb	C=O	cb		2R-trans
45	B12	cb	C=O	cb		2R-trans









Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
46	B2	cb	C=O	cb		B-trans
47	B2	cb	C=O	cb		2R-trans
48	B2	cb	C=O	cb		2R-trans
49	B2	cb	C=O	cb		2R-trans
50	B2	cb	C=O	cb		2R-trans
51	B2	cb	C=O	cb		2R-trans








Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
52	B2	cb	C=O	cb		2R-trans
53	B2	cb	C=O	cb		2R-trans
54	B2	cb	C=O	cb		2R-trans
55	B2	cb	C=O	cb		2R-trans
56	B3b	cb	C=O	cb		2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
57	B2	cb	C=O	cb		B-trans
58	B2	cb	C=O	cb		2R-cis
59	B2	cb	C=O	cb		B-trans
60	B2	cb	C=O	cb		trans
170	B3b	cb	C=O	cb		2R-trans






Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
61	B2	cb	C=O	cb		2R-trans
62	B2	cb	C=O	cb		2R-trans
63	B2	cb	C=O	cb		2R-trans
64	B3a	cb	C=O	cb		2R-trans
65	B2	cb	C=O	cb		2R-trans
66	B2	cb	C=O	cb		B-trans






Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
67	B3b	cb	C=O	cb		2R-trans
68	B2	cb	C=O	cb		2R-trans
69	B3a	cb	C=O	cb		2R-trans
5	B3b	cb	C=O	cb		2R-trans
70	B2	cb	C=O	cb		2R-trans
161	B2	cb	C=O	cb		2R-trans
71	B3a	cb	C=O	cb		2R-trans
136	B3b	cb	C=O	cb		2S-trans









Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
137	B3b	cb	C=O	cb		2R-cis
138	B3b	cb	C=O	cb		2S-cis
72	B3a	cb	C=O	cb		2R-trans
12	B7	cb	C=O	cb		2R-trans
73	B2	cb	C=O	cb		2R-trans
19	B2	cb	C=O	cb		2R-trans
74	B2	cb	C=O	cb		2R-trans
75	B2	cb	C=O	cb		2R-trans











Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
4	B3a	cb	C=O	cb		2R-trans
76	B3a	cb	C=O	cb		2R-trans
77	B2	cb	C=O	cb		2R-trans m.p. 119.6 °C
139	B2	cb	C=O	cb		2R-cis
140	B2	cb	C=O	cb		2S-cis
141	B2	cb	C=O	cb		2S-trans
78	B2	cb	C=O	cb		2R-trans; HCl(1:2); H ₂ O(1:1)











Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
142	B2	cb	C=O	cb		2R-trans; succinate (1:2)
143	B2	cb	C=O	cb		2R-trans; malonate (1:2)
144	B13	cb	C=O	cb		2R-trans
120	B3b	cb	C=O	cb		2R-trans
79	B2	cb	C=O	cb		2R-trans
166	B3b	cb	C=O	cb		2R-trans
80	B2	cb	C=O	cb		2R-trans
81	B3b	cb	C=O	cb		2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
82	B3b	cb	C=O	cb		2R-trans
83	B2	cb	C=O	cb		2R-trans
14	B2	cb	C=O	cb		2R-trans
84	B3b	cb	C=O	cb		2R-trans
85	B10	cb	C=O	cb		2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
86	B9	cb	C=O	cb		2R-trans
87	B9	cb	C=O	cb		2R-trans
88	B8	cb	C=O	cb		2R-trans
89	B3b	cb	C=O	cb		2R-trans
90	B3b	cb	C=O	cb		[2R- [2 α ,4 β (S)]]











Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
91	B8	cb	C=O	cb		[2R-[2α,4β(S)]]
92	B2	cb	C=O	cb		2R-trans
93	B3b	cb	C=O	cb		2R-trans
94	B3b	cb	C=O	cb		B-trans
169	B3b	cb	C=O	cb		2R-trans
96	B2	cb	C=O	cb		B-trans
145	B3b	cb	C=O	cb		2S-trans
146	B3b	cb	C=O	cb		2R-cis

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
147	B3b	cb	C=O	cb		2S-cis
173		cb	C=O	cb		
97	B4c	-CH ₂ -	C=O	cb		2R-trans
98	B2	cb	C=O	-CH ₂ -	-H	2R-trans
99	B2	cb	C=O		-H	2R-trans
159	B2	cb	C=O		-H	2R-trans
167	B3b	cb	C=O			2R-trans
160	B2	cb	C=O		-H	2R-trans
100	B2	cb	C=O		-H	2R-trans
101	B2	cb	C=O		-H	2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
148	B2	cb	C=O		-H	2S-trans
149	B2	cb	C=O		-H	2R-cis
150	B2	cb	C=O		-H	2S-cis
171	B3b	cb	C=O		-H	2R-trans
172	B3b	cb	C=O		-H	2R-trans
102	B2	cb	C=O		-H	2R-trans
151	B2	cb	C=O		-H	2R-trans
103	B2	cb	C=O		-H	2R-trans
104	B2	cb	C=O	-CH ₂ -		2R-trans
105	B2	cb	C=O	-CH ₂ -		2R-trans


Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
106	B2	cb	C=O	-CH ₂ -		2R-trans
107	B3b	cb	C=O	-CH ₂ -		2R-trans
13	B8	cb	C=O			2R-trans, HCl(1:3); H ₂ O(1:1)
108	B2	cb	C=O			2R-trans HCl(1:2) H ₂ O(1:1)
109	B2	cb	C=O			2R-trans
110	B3b	cb	C=O			[2R-[2α,4β(E)]]
111	B2	cb	C=O			2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
112	B2	cb	C=O			2R-trans
152	B4c	cb	C=O			B-trans
113	B4c	cb	C=O			B-trans HCl(1:3) H ₂ O(1:3)
114	B4b	cb	C=O			B-trans
115	B3b	cb	C=O			B-trans
116	B4c	cb	C=O			2R-trans

Comp. No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
6	B4a		C=O	cb		2R-trans
117	B2		C=O	cb		2R-trans
168	B2	cb		cb		2R-trans
118	B2	cb		cb		B-trans
119	B2	cb		cb		B-trans

cb = Covalent Bond


-63-

Table 2:

Co No.	Exp. No.	R¹	Alk ^a	Y	Alk ^b	L	Physical data
10	B6		cb	C=O	cb		[2α,4α(2R*,4S*)]
11	B6		cb	C=O	cb		[2α,4β(2R*,4S*)]

cb = Covalent Bond

5


Table 3:

Co No.	Exp. No.	Alk ^a	Y	Alk ^b	L	Physical data
153	B15	cb	C=O	cb		2R-trans

cb = Covalent Bond

-64-

Table 4:




Co No.	Exp No.	Alk ^a	Y	Alk ^b	L	Physical data
154	B1a	-CH ₂ -	cb	cb		2R-cis
155	B1a	-CH ₂ -	cb	cb		2R-trans
156	B1b	cb	cb	cb	-H	2R-trans
157	B2	cb	C=O	cb		2R-trans
158	B2	cb	C=O	cb		2R-trans

cb = Covalent Bond


5

Table 5:



Co No.	Exp No.	Alk ^a	Y	Alk ^b	L	Physical data
175	B1b	cb	cb	cb	H	cis
174	B1a	-CH ₂ -	cb	cb		
176	B2	cb	C=O	cb		cis

-65-

Co No.	Exp No.	Alk ^a	Y	Alk ^b	L	Physical data
177	B2	cb	C=O	cb		cis

cb = Covalent Bond

Analytical data

For a number of compounds, either melting points, LCMS data or optical rotations were recorded.

Melting points

If possible, melting points (or ranges) were obtained with a Büchi melting point apparatus B-545. The heating medium is a metal block. The melting of the sample is visually observed by a magnifying lens and a big light contrast. Melting points are measured with a temperature gradient of either 3 or 10 degrees Celsius/minute. Melting points are given in Table 6.

Table 6

Compound no.	Result (°C)
1	115.9-119.7
2	160.6-163.2
3	149.9-151.7
4	180.5-182.1
5	87.8-121.4
6	87.7-111.2
7	141.0-177.3
8	162.3-164.3
9	122.1-123.8
10	97.0-120.4
11	111.9-125.4
12	66.7-79.0
13	284.5-288.6
14	107.4-116.1
15	188.1-190.3
19	140.3-144.8
22	98.3-119.9
29	142.9-146.5
31	153.1-155.2
32	83.3-95.5

-66-

Compound no.	Result (°C)
33	82.7-98.6
34	80.7-95.5
37	298.1-319.7
38	83.2-110.2
39	279.4-280.9
46	81.3-107.2
49	145.3-149.6
50	92.1-100.7
51	108.9-127.3
52	93.9-104.6
53	156.6-161.0
54	107.6-122.2
55	96.7-106.3
56	171.3-181.5
57	167.4-169.4
58	92.5-102.6
59	79.1-98.2
60	100.5-121.4
62	91.4-120.3
63	86.0-99.4
64	133.6-159.5
65	102.3-105.8
69	108.6-120.6
71	93.5-127.3
72	91.6-103.2
73	100.5-110.5
75	78.8-93.8
76	76.2-93.8
77	273.6-295.2
79	74.3-100.3
80	106.7-126.1
81	85.3-120.6
82	91.9-121.2
83	86.9-102.1
84	92.2-126.1
85	145.4-147.2
88	70.6-108.7
89	96.1-109.4
90	111.9-120.1
91	91.5-108.1
92	100.7-117.9
93	184.1-192.4
98	177.1-180.6
99	65.9-83.0
100	76.1-100.1

-67-

Compound no.	Result (°C)
102	72.9-93.5
103	83.7-100.8
104	105.1-108.5
106	77.2-99.1
108	314.8-335.8
109	95.4-107.7
110	84.6-111.8
111	87.3-109.3
113	252.3-291.7
116	102.8-125.6
117	158.2-160.5
122	177.5°C

LCMS conditions

- The HPLC gradient was supplied by a Waters Alliance HT 2790 system with a column heater set at 40°C. Flow from the column was split to a Waters 996 photodiode array (PDA) detector and a Waters-Micromass ZQ mass spectrometer with an electrospray ionization source operated in positive and negative ionization mode.
- Reversed phase HPLC was carried out on a Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammoniumacetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 6.5 min., to 100 % B in 1 min, 100% B for 1 min. and reequilibrate with 100 % A for 1.5 min. An injection volume of 10 mL was used.
- Mass spectra were acquired by scanning from 100 to 1000 in 1 s using a dwell time of 0.1 s. The capillary needle voltage was 3kV and the source temperature was maintained at 140°C. Nitrogen was used as the nebulizer gas. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system. Data is given in Table 7.

Table 7

Compound no.	LCMS MS(MH+)
16	661
18	703

-68-

Compound no.	LCMS MS(MH+)
20	711
21	724
22	701
23	703
24	753
26	809
27	699
28	749
30	654
35	703
36	703
42	756
48	719
61	747
70	693
74	692
94	740
96	703
101	651
105	731
107	691
114	803
115	791
118	859
119	767
124	700
125	673
126	673
127	673
128	737
129	709
130	709
131	693
132	687
133	687

-69-

Compound no.	LCMS MS(MH+)
134	687
135	701
136	677
137	677
138	677
139	709
140	709
141	709
142	709
143	709
144	725
145	681
146	681
147	681
148	651
149	651
150	651
151	677
153	595
154	709
155	709
156	619
157	723
158	745

Optical rotations

Optical rotations were recorded on a polarimeter (Perkin Elmer) at 20°C. Specifics on concentration, wavelength and solvent are given in Table 8.

5

Table 8

Compound no.	$[\alpha]$	Wavelength (nm)	Concentration (w/v%)	Solvent
18	-33.77°	365	0.4086	CH ₃ OH
159	-35.56°	365	0.4302	CH ₃ OH
160	-33.66°	365	0.5288	CH ₃ OH

-70-

Compound no.	$[\alpha]$	Wavelength (nm)	Concentration (w/v%)	Solvent
161	-34.75°	365	0.4058	CH ₃ OH
162	-6.72°	436	0.6400	CH ₃ OH
163	-33.2°	365	0.4638	CH ₃ OH
164	-34.1°	365	0.4340	CH ₃ OH
165	-34.43°	365	0.4298	CH ₃ OH
166	-33.95°	365	0.4094	CH ₃ OH
167	-29.91°	365	0.4848	CH ₃ OH
168	-29.12°	365	0.4602	CH ₃ OH
169	-32.32°	365	0.4548	CH ₃ OH
170	-33.3°	365	0.4354	CH ₃ OH
171	-35.06°	365	0.4164	CH ₃ OH
172	-35.84°	365	0.4380	CH ₃ OH
173	-34.53°	365	0.4054	CH ₃ OH

C. Pharmacological example

Example C.1 : Binding experiment for h-NK₁, h-NK₂ and h-NK₃ receptors

- 5 The compounds according to the invention were investigated for interaction with various neurotransmitter receptors, ion channels and transporter binding sites using the radioligand binding technique. Membranes from tissue homogenates or from cells, expressing the receptor or transporter of interests, were incubated with a radioactively labelled substance ([³H]- or [¹²⁵I] ligand) to label a particular receptor. Specific receptor
- 10 binding of the radioligand was distinguished from the non-specific membrane labelling by selectively inhibiting the receptor labelling with an unlabelled drug (the blank), known to compete with the radioligand for binding to the receptor sites. Following incubation, labelled membranes were harvested and rinsed with excessive cold buffer to remove non-bound radioactivity by rapid filtration under suction. Membrane bound radioactivity
- 15 was counted in a scintillation counter and results were expressed in counts per minute (cpm).

The compounds were dissolved in DMSO and tested at 10 concentrations ranging from 10⁻¹⁰ to 10⁻⁵ M.

- 20 The ability of the compounds according to the invention to displace [³H]-Substance P from cloned human h-NK₁ receptors expressed in CHO cells, to displace

-71-

[³H]-SR-48968 from cloned human h-NK₂ receptors expressed in Sf9 cells, and to displace [³H]-SR-142801 from cloned human h-NK₃ receptors expressed in CHO cells was evaluated.

- 5 The pIC₅₀ data for the h-NK₁, h-NK₂ and h-NK₃ receptor testing for a representative selection of compounds are presented in Table 9.

All selected compounds show (sub)nanomolar affinity for the h-NK₁ receptor most of them with more than 100-fold selectivity towards the h-NK₂ and h-NK₃ receptors.

10 Example C.2 : Signal transduction

- This test evaluates in vitro functional NK₁ antagonistic activity. For the measurements of intracellular Ca⁺⁺ concentrations the cells were grown on 96-well (black wall/transparent bottom) plates from Costar for 2 days until they reached confluence. The cells were loaded with 2 µM Fluo3 in DMEM containing 0.1% BSA and 2.5 mM
- 15 probenecid for 1 h at 37°C. They were washed 3x with a Krebs buffer (140 mM NaCl, 1 mM MgCl₂·6H₂O, 5 mM KCl, 10 mM glucose, 5 mM HEPES; 1.25 mM CaCl₂; pH 7.4) containing 2.5 mM probenecid and 0.1 % BSA (Ca⁺⁺-buffer). The cells were preincubated with a concentration range of antagonists for 20 min at RT and Ca⁺⁺-
- 20 signals after addition of the agonists were measured in a Fluorescence Image Plate Reader (FLIPR from Molecular Devices, Crawley, England). The peak of the Ca⁺⁺-transient was considered as the relevant signal and the mean values of corresponding wells were analysed as described below.

- The sigmoidal dose response curves were analysed by computerised curve-fitting, using the GraphPad Program. The EC₅₀-value of a compound is the effective dose showing
- 25 50 % of maximal effect. For mean curves the response to the agonist with the highest potency was normalised to 100 %. For antagonist responses the IC₅₀-value was calculated using non-linear regression.

Table 9

Co No.	h-NK ₁ pIC ₅₀	h-NK ₂ pIC ₅₀	h-NK ₃ pIC ₅₀
5	10.0	6.1	6.3
110	10.0	-	-
97	9.5	6.3	6.4
45	9.5	-	-
22	9.4	6.2	6.5

-72-

Co No.	h-NK ₁ pIC ₅₀	h-NK ₂ pIC ₅₀	h-NK ₃ pIC ₅₀
151	9.4	6.2	6.4
80	9.3	6.1	6.6
62	9.2	6.4	6.6
104	9.2	5.8	5.8
8	9.2	-	-
78	9.1	6.4	6.0
12	9.1	6.0	6.1
39	9.1	6.0	6.0
113	9.0	6.4	6.4
16	9.0	6.3	6.8
56	9.0	6.3	6.7
143	9.0	6.1	6.3
36	9.0	6.1	6.1
77	9.0	6.1	5.6
106	9.0	6.0	6.3
102	9.0	-	-
6	9.0	-	-
3	8.9	6.3	6.6
142	8.9	6.2	6.6
51	8.9	6.2	6.4
9	8.9	6.2	6.3
13	8.9	6.2	6.0
32	8.8	6.2	6.8
139	8.8	6.1	6.5
4	8.8	5.2	6.7
108	8.8	-	-
89	8.6	6.2	6.2
116	8.6	6.1	6.8
2	8.6	5.8	5.2
42	8.6	-	-
140	8.5	5.4	5.3
85	8.5	-	-
37	8.4	6.3	6.6
65	8.4	6.2	6.6

-73-

Co No.	h-NK ₁ pIC ₅₀	h-NK ₂ pIC ₅₀	h-NK ₃ pIC ₅₀
133	8.4	5.9	6.1
79	8.2	6.5	6.4
64	8.1	6.4	6.4
7	8.1	6.0	6.0
141	8.1	5.4	5.4
132	8.0	5.7	5.5
134	7.7	5.6	<5
119	7.6	6.0	6.0
90	7.5	6.5	6.9
11	7.4	6.2	6.6
26	7.4	6.0	6.0
10	7.3	6.4	6.2
144	-	5.9	6.2

Example C.3 : Antiemetic effects : Loperamide-induced retching in ferrets

Unless otherwise specified, in all subsequent tests Compounds 3 and 77 were evaluated.

- 5 The antiemetic effects have been determined using the loperamide-induced retching model (i.e. retching induced by an opioid) in ferrets. To exclude species differences in antiemetic activity, both compounds have also been tested for antiemetic activity against apomorphine in dogs.

- 10 Antagonism of emesis induced by the peripherally selective opioid loperamide (0.31 mg/kg, s.c.) was studied over a 1 h-period starting immediately after the emetic challenge in ferrets pretreated with test compound or solvent. In control animals pretreated with solvent, loperamide induced pronounced retching (mean \pm SD: 95 ± 39 counts; $n = 529$) and, to a lesser extent, vomiting (5 ± 4).

- 15 Table 10 lists the ED₅₀s (95% CL; mg/kg) of Compounds 3 and 77 obtained for inhibition (< 20 retches; 2.0% false positives) and blockade (= 0 retches; 0% false positives) of loperamide-induced retching at several time intervals after oral, s.c. and i.v. administration.

-74-

Table 10: ED₅₀s (95% CL; mg/kg) for inhibition and blockade of loperamide-induced retching as a function of time after oral, s.c. and i.v. administration.

Time (h)	ED ₅₀ s (95% CL; mg/kg)	
	Compound 3	Compound 77
Inhibition of retching:		
Oral route:		
1	0.72 (0.32-1.62)	0.31 (0.14-0.71)
2	0.96 (0.52-1.74)	0.080 (0.036-0.18)
4	1.25 (0.82-1.92)	0.26 (0.17-0.38)
8	1.25 (0.82-1.92)	0.29 (0.22-0.40)
16	1.26 (0.82-1.94)	0.73 (0.40-1.33)
32	3.81 (2.08-6.97)	~ 2.5 (- - -) ^{a)}
64	> 10	not tested
Subcutaneous route:		
1	0.55 (0.30-1.01)	0.18 (0.10-0.33)
Intravenous route:		
1	0.39 (0.26-0.28)	0.15 (0.10-0.22)
Blockade of retching:		
Oral route:		
1	1.65 (0.91-3.02)	0.72 (0.40-1.33)
2	2.18 (1.2-4.0)	0.42 (0.23-0.76)
4	1.25 (0.82-1.92)	0.77 (0.57-1.05)
8	2.89 (1.58-5.29)	0.34 (0.25-0.46)
16	2.89 (1.58-5.29)	1.66 (0.91-3.04)
32	5.0 (3.2-7.7)	> 2.5
64	> 10.0	not tested
Subcutaneous route:		
1	0.96 (0.52-1.75)	0.32 (0.21-0.49)
Intravenous route:		
1	0.88 (0.59-1.3)	0.26 (0.17-0.39)

^{a)} At 2.5 mg/kg, only 1 out of 5 ferrets showed less than 20 retches. However, the number of retches obtained in the 5 ferrets (42, 21, 20, 40, 16) indicates that the ED₅₀ for inhibition of retching (< 20 retches) is close to 2.5 mg/kg.

After oral administration, retching was inhibited (< 20 retches) by at graphically estimated peak-effect ED₅₀s of 0.16, 1.0 and 0.85 mg/kg, respectively, and completely blocked (= 0 retches) at 0.34, 1.4 and 1.5 mg/kg, respectively. At 4 times the peak-effect dose, the compounds showed a rapid onset of action (< 1.0 h) and a duration of action of 16 h for Compound 77 and 32 h for Compound 3.

One hour after s.c. injection, retching was inhibited at 0.18, 0.55 and 1.25 mg/kg, respectively, and completely blocked at 0.32, 0.96 and 3.16 mg/kg, respectively. The ratio of oral ED₅₀ (at time of peak effect) over subcutaneous ED₅₀ (obtained at 1 h) was small for the three compounds: Compound 77 (1.1) and Compound 3 (1.4-1.8).

-75-

Table 11 compares the antiemetic activity of several prior-art NK₁ antagonists. Compound 77 shows an excellent antiemetic activity, comparable with that of GR-203040.

- 5 **Table 11:** ED₅₀s (95% CL; mg/kg) for blockade of loperamide (0.31 mg/kg, s.c.)-induced retching in ferrets at 1 h after subcutaneous or 2 h after oral administration.

Compound	ED ₅₀ (95% confidence limits; mg/kg)		Ratio
	s.c. route (-1 h)	p.o. route (-2 h)	
Compound 3	0.96 (0.52-1.75)	2.18 (1.2-4.0)	2.3
Compound 77	0.32 (0.21-0.49)	0.42 (0.23-0.76)	1.3
GR-203040 ^{a)}	0.064 (0.037-0.11)	0.20 (0.12-0.35)	3.1
L-760735 ^{b)}	0.31 (- - -) ^g	not tested	-
CP-99994 ^{c)}	0.63 (0.36-1.1)	> 10	> 16
Aprepitant/MK-869 ^{d)}	> 1.25	3.1 (1.9-5.0)	< 2.5
CP-96345 ^{e)}	> 10	not tested	-
SDZ-NKT-343 ^{f)}	not tested	> 2.5	-

- ^{a)} Ward *et al.* Discovery of an orally bioavailable NK₁ receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with
10 potent antiemetic activity. *J Med Chem* 38:4985-4992, 1995.
- ^{b)} McAllister *et al.* Differential display analysis of the mechanisms of action of antidepressant drugs. *Soc Neurosci*, Abstracts 25: Part 2 Abs. 733.11, 1999.
- ^{c)} Piedimonte *et al.* A new NK₁ receptor antagonist (CP-99,994) prevents the increase
15 in tracheal vascular permeability produced by hypertonic saline. *J Pharmacol Exp Ther* 266:270-273, 1993.
- ^{d)} Kramer *et al.* Distinct mechanism for antidepressant activity by blockade of central substance P receptors. *Science* 281:1640-1645, 1998.
- ^{e)} Snider *et al.* Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. *Proc Natl Acad Sci* 88:10042-10044, 1991.
- 20 ^{f)} Walpole *et al.* 2-Nitrophenylcarbamoyl-(S)-prolyl-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a potent human NK₁ tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. *J Med Chem* 41:3159-3173, 1998.
- ^{g)} ED₅₀ estimated based on a limited number of animals tested per dose group.


-76-

Compound 77 was also found more potent than Compound 3 1 h after i.v. injection, both for inhibition of retching (ED_{50} : 0.15 and 0.39 mg/kg, respectively) and for blockade of retching (ED_{50} : 0.26 and 0.88 mg/kg, respectively).

-77-

Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound according to Formula (I)



- the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein :
- n is an integer, equal to 0, 1 or 2 ;
- m is an integer, equal to 1 or 2, provided that if m is 2, then n is 1 ;
- p is an integer equal to 1 or 2 ;
- Q is O or NR³ ;
- X is a covalent bond or a bivalent radical of formula -O-, -S- or -NR³- ;
- each R³ independently from each other, is hydrogen or alkyl ;
- each R¹ independently from each other, is selected from the group of Ar¹, Ar¹-alkyl and di(Ar¹)-alkyl ;
- q is an integer equal to 0 or 1 ;
- R² is alkyl, Ar², Ar²-alkyl, Het¹ or Het¹-alkyl ;
- Y is a covalent bond or a bivalent radical of formula -C(=O)- or -SO₂-;
- each Alk represents, independently from each other, a covalent bond; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more alkyl, phenyl, halo, cyano, hydroxy, formyl and amino radicals ;
- L is selected from the group of hydrogen, alkyloxy, Ar³-oxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(Ar³)amino, Ar³, Ar³-carbonyl, Het² and Het²-carbonyl;
- Ar¹ is phenyl, optionally substituted with 1, 2 or 3 substituents each independently from each other selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy ;

-78-

- Ar² is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl ;
- Ar³ is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents each independently from each other selected from the group of alkyloxy, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano;
- Het¹ is a monocyclic heterocyclic radical selected from the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl ; each monocyclic and bicyclic heterocyclic radical may optionally be substituted on any atom by a radical selected from the group of halo and alkyl ;
- Het² is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl ; or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromenyl, benzimidazolyl, imidazo [1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl ; each monocyclic and bicyclic radical optionally substituted with one or more radicals selected from the group of Ar¹, Ar¹alkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkyloxyalkyl and alkyloxycarbonyl ; and
- alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; optionally substituted on one or more

-79-

carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino radicals.

2. A pharmaceutical composition according to claim 1, characterized in that
- 5 n is 1 ;
 m is 1 ;
 p is 1 ;
 Q is O ;
 X is a covalent bond ;
- 10 each R¹ is Ar¹ or Ar¹-alkyl ;
 q is 0 or 1 ;
 R² is Ar² ;
 Y is a covalent bond or a bivalent radical of formula -C(=O)- or -SO₂- ;
 each Alk represents, independently from each other, a covalent bond; a bivalent
- 15 straight or branched, saturated or unsaturated hydrocarbon radical
 having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated
 hydrocarbon radical having from 3 to 6 carbon atoms ; each radical
 optionally substituted on one or more carbon atoms with one or more
 phenyl, halo, cyano, hydroxy, formyl and amino radicals ;
- 20 L is selected from the group of hydrogen, alkyloxy, Ar³-oxy, alkyloxycarbonyl,
 mono- and di(alkyl)amino, mono- and di(Ar³)amino, Ar³ and Het² ;
 Ar¹ is phenyl, optionally substituted with 1, 2 or 3 alkyl radicals ;
 Ar² is phenyl, optionally substituted with 1, 2 or 3 alkyl radicals ;
 Ar³ is phenyl, optionally substituted with 1, 2 or 3 substituents each
- 25 independently from each other selected from the group of alkyloxy, alkyl,
 halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo
 [1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and
 cyano ;
- Het² is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl,
 piperidinyl, morpholinyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl,
 isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and
 pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of
 benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, chromenyl and
 benzimidazolyl ; each monocyclic and bicyclic radical optionally substituted
- 30 with one or more radicals selected from the group of Ar¹, Ar¹-alkyl, halo,
 hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo and alkyloxycarbonyl ; and
- 35

-80-

alkyl is a straight hydrocarbon radical having 1 to 6 carbon atoms, optionally substituted with one or more halo radicals .

3. A pharmaceutical composition according to any one of claims 1 to 2,
5 characterized in that R¹ is Ar¹methyl and attached to the 2-position or R¹ is Ar¹ and attached to the 3-position.
4. A pharmaceutical composition according to any one of claims 1 to 3,
10 characterized in that the R²-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.
5. A pharmaceutical composition according to claim 1, characterized in that the compound according to Formula (I) is selected from the group of :
15
 - o {4-[4-(1-Benzoyl-piperidin-4-yl)-piperazin-1-yl]-2-benzyl-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone and
 - o (2-Benzyl-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-piperidin-4-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone.
6. A pharmaceutical composition according to claim 1, characterized in that the
20 compound according to Formula (I) is a compound with compound number 5, 110, 97, 45, 22, 151, 80, 62, 104, 8, 78, 12, 39, 113, 16, 56, 143, 36, 77, 106, 102, 6, 3, 142, 51, 9, 13, 32, 139, 4, 108, 89, 116, 2, 42, 140, 85, 37, 65, 133, 79, 64, 7, 141, 132, 134, 119, 90, 11, 26, 10 and 144 as cited in the Experimental section.
25
7. A pharmaceutical composition according to any one of claims 1 to 6, characterized in that it is formulated for simultaneous, separate or sequential use.
8. A pharmaceutical composition according to any one of claims 1 to 7,
30 characterized in that the opioid analgesic is one or more compounds selected from the group of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil and sufentanil; or a
35 pharmaceutical acceptable salt or derivative thereof.
9. A pharmaceutical composition according to claim 8, characterized in that the

-81-

opioid analgesic is one or more compounds selected from the group of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and derivatives thereof.

- 5 10. A pharmaceutical composition according to claim 9, characterized in that the opioid analgesic is one or more compound selected from the group of morphine sulphate and fentanyl citrate.
- 10 11. A pharmaceutical composition according to any one of claims 1 to 10, characterized in that it is in a form suitable to be orally administered.
12. The use of a pharmaceutical composition according to any one of claims 1 to 11 for the manufacture of a medicament for the prevention and/or treatment of pain and/or nociception.
- 15 13. The use of a pharmaceutical composition according to any one of claims 1 to 11 for the manufacture of a medicament for the opioid-based prevention and/or treatment of acute and chronic pain, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments.
- 20 14. The use of a pharmaceutical composition according to any one of claims 1 to 11 for the manufacture of a medicament for the prevention and/or treatment of emesis in opioid-based treatments of pain.
- 25 15. The use of a pharmaceutical composition according to claim 14 for the manufacture of a medicament for the prevention and/or treatment of nausea and vomiting in opioid-based treatments of pain.
- 30 16. The use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for the manufacture of a medicament for the prevention and/or treatment of respiratory depression in opioid-based treatments of pain.
- 35 17. The use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist

-82-

5 according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for the manufacture of a medicament for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110415 A3

(51) International Patent Classification?: **A61K 31/33**,
31/496, 31/485, 31/4468, A61P 25/00, 25/02, 25/04,
11/00, 1/08, A61K 31/433, A61P 25/36

c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30,
B-2340 Beerse (BE).

(21) International Application Number:
PCT/EP2004/051048

(74) Common Representative: **JANSSEN PHARMACEU-
TICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date: 7 June 2004 (07.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP03/50220 10 June 2003 (10.06.2003) EP

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JANSSENS, Frans**,
Eduard [BE/BE]; c/o Janssen Pharmaceutica N.V., Turn-
houtseweg 30, B-2460 Beerse (BE). **SOMMEN, François**,
Maria [BE/BE]; c/o Janssen Pharmaceutica N.V., Turn-
houtseweg 30, B-2340 Beerse (BE). **DE BOECK, Benoît**,
Christian, Albert, Ghislain [BE/BE]; c/o Janssen Phar-
maceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).
LEENAERTS, Joseph, Elisabeth [BE/BE]; c/o Janssen
Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse
(BE). **VAN ROOSBROECK, Yves, Emiel, Maria**
[BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg
30, B-2340 Beerse (BE). **MEERT, Theo, Frans** [BE/BE];


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,

[Continued on next page]

(54) Title: SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANAL-
GESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED
TREATMENTS



and/or treatment of emesis, pain and/or nociception, in particular in opioidbased acute and chronic pain treatments, more in particular in inflammatory, postoperative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments and the use of an NK₁-receptor antagonist for the manufacture of a medicament for the prevention and/or treatment of respiratory depression in opioid-based treatments of pain. The pharmaceutical formulations according to the invention comprise a pharmaceutically acceptable carrier and, as active ingredients, a therapeutically effective amount of an opioid analgesic and NK₁-antagonists according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. The pharmaceutical composition according to the invention reduces to a large extent a number of unwanted sideeffects associated with opioid analgesics, in particular emesis, respiratory depression and tolerance, thereby increasing the total tolerability of said opioids in pain treatment.

(57) Abstract: This invention concerns novel formulations for opioid-based treatments of pain and/or nociception comprising opioid analgesics and 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK₁ antagonistic activity, the use of said formulation for the manufacture of a medicament for the prevention



TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

10 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/051048

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/33 A61K31/496 A61K31/485 A61K31/4468 A61P25/00
A61P25/02 A61P25/04 A61P11/00 A61P1/08 A61K31/433
A61P25/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, FSTA, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 197 772 B1 (JANSSENS FRANS EDUARD ET AL) 6 March 2001 (2001-03-06) cited in the application column 1, lines 10-14,39 - column 3, line 56 column 16, line 49 - column 18, line 32; table 2	1-5,7-9, 11,14,15
X	US 5 880 132 A (HILL RAYMOND GEORGE) 9 March 1999 (1999-03-09) cited in the application column 1, lines 7-10	16,17
Y	column 2 - column 3 column 26, lines 23-60 column 52, line 65 - column 53, line 8	1-17
	----- --/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document relating to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

8 November 2004

Date of mailing of the international search report

02/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Houyvet, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB 2 287 404 A (PFIZER) 20 September 1995 (1995-09-20) page 1, lines 5-9,20-31 page 2, lines 8,9,15-17,19 -----	1-17
P,X	WO 2004/033428 A (JANSSENS FRANS EDUARD ; SOMMEN FRANCOIS MARIA (BE); DE BOECK BENOIT CH) 22 April 2004 (2004-04-22) cited in the application page 1, lines 5-9 page 6, line 30 - page 10, line 12 page 18, lines 15,16,24-31 page 19, lines 7-9 page 20, lines 12-27; tables 1-5 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/051048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6197772	B1	06-03-2001	
		AT 188691 T	15-01-2000
		AU 704155 B2	15-04-1999
		AU 7493296 A	22-05-1997
		BR 9611184 A	30-03-1999
		CA 2234096 A1	09-05-1997
		CN 1438220 A	27-08-2003
		CN 1205699 A, B	20-01-1999
		CY 2177 A	23-08-2002
		CZ 9801322 A3	16-09-1998
		DE 69606196 D1	17-02-2000
		DE 69606196 T2	21-09-2000
		EA 980404 A1	29-10-1998
		WO 9716440 A1	09-05-1997
		EP 0862566 A1	09-09-1998
		ES 2143238 T3	01-05-2000
		GR 3033154 T3	31-08-2000
		HR 960507 A1	28-02-1998
		HU 9802985 A2	28-10-1999
		IL 123962 A	11-01-2001
		JP 11514634 T	14-12-1999
		JP 3073238 B2	07-08-2000
		NO 981534 A	24-06-1998
		NZ 321575 A	28-05-1999
		PL 327406 A1	07-12-1998
		PT 862566 T	30-06-2000
		SI 862566 T1	30-04-2000
		TR 9800756 T2	21-07-1998
		TW 460473 B	21-10-2001
		US 6521621 B1	18-02-2003
		US RE37886 E1	15-10-2002
		ZA 9609090 A	29-04-1998
		DK 862566 T3	13-06-2000
US 5880132	A	09-03-1999	
		AT 214945 T	15-04-2002
		AU 705523 B2	27-05-1999
		AU 4185496 A	19-07-1996
		CA 2207650 A1	04-07-1996
		DE 69526115 D1	02-05-2002
		DE 69526115 T2	02-10-2002
		EP 0799056 A1	08-10-1997
		ES 2173986 T3	01-11-2002
		WO 9620009 A1	04-07-1996
		JP 11500104 T	06-01-1999
		US 6180624 B1	30-01-2001
GB 2287404	A	20-09-1995	NONE
WO 2004033428	A	22-04-2004	
		WO 2004056772 A1	08-07-2004
		WO 2004033428 A1	22-04-2004

THIS PAGE BLANK (USPTO)